Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/19/2023 | Outperform → Sector Perform | RBC Capital Mkts | |
| 2/24/2022 | $14.00 → $16.00 | Buy | HC Wainwright & Co. |
| 12/13/2021 | $12.00 → $20.00 | Outperform | Evercore ISI Group |
| 12/7/2021 | $9.00 → $11.00 | Outperform | RBC Capital |
| 10/18/2021 | $8.00 → $9.00 | Outperform | RBC Capital |
| 9/14/2021 | $10.00 → $14.00 | Buy | HC Wainwright & Co. |
| 7/29/2021 | $9.00 | Buy | BTIG Research |
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se
LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced the appointment of William Mezzanotte, MD, MPH to its Board of Directors. Dr. Mezzanotte brings decades of vast development and commercial experience to the Board, including the development and approval of 30 products across multiple therapeutic areas. “Bill is a biopharmaceutical veteran with a proven drug development track record, including the approval of several drugs within the respiratory field,” c
15-12G - BELLUS Health Inc. (0001259942) (Filer)
S-8 POS - BELLUS Health Inc. (0001259942) (Filer)
S-8 POS - BELLUS Health Inc. (0001259942) (Filer)
LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R
BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced the positive outcome of the BELLUS shareholders ("Shareholders") vote at this morning's special meeting of the Shareholders (the "Special Meeting") held in-person, approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a corporation existing under the laws of Canada and a wholly-owned subsidiary of GSK plc (NYSE:GSK, LSE: GSK))) ("GSK"), will acquire, for a purchase price of US$14.75 in cash per share, all of the issued and outstanding common shares of BELLUS (the
Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS" or the "Company") today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding of a special meeting (the "Special Meeting") of shareholders of BELLUS ("Shareholders") on June 16, 2023. At the Special Meeting, Shareholders will be asked to consider and, if deemed advisable, to adopt a special resolution (the "Arrangement Resolution") approving the previously-announced statutory plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which 14934792 Canada Inc. (the "Purchaser"), a co
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff. The pharmaceutical industry is experiencing strong interest in M&A due to anticipated revenue erosion of approximately $200 billion by the end of the decade. The latest examples include Astellas Pharma Inc (OTC:ALPMY) acquiring American firm Iveric Bio Inc (NASDAQ:ISEE) for $5.9 billion, Pfizer Inc (NYSE:PFE) proposing a $43 billion acquisition of Seagen Inc (NASDAQ:SGEN), GSK plc (NYSE:GSK) agreeing to acquire BELL
RBC Capital analyst Gregory Renza reiterates BELLUS Health (NASDAQ:BLU) with a Sector Perform and maintains $14.75 price target.
BELLUS Health (NASDAQ:BLU) reported its Q1 earnings results on Friday, May 12, 2023 at 04:00 PM. Here's what investors need to know about the announcement. Earnings BELLUS Health missed estimated earnings by 11.11%, reporting an EPS of $-0.2 versus an estimate of $-0.18. Revenue was down $1 thousand from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.04 which was followed by a 0.65% increase in the share price the next day. Listen to the earnings announcement yourself by clicking here. To track all earnings releases for BELLUS Health visit their earnings calendar here. This article was generated by Benzinga's automated content engine and r
SC 13G - BELLUS Health Inc. (0001259942) (Subject)
SC 13G/A - BELLUS Health Inc. (0001259942) (Subject)
SC 13G - BELLUS Health Inc. (0001259942) (Subject)
RBC Capital Mkts downgraded BELLUS Health from Outperform to Sector Perform
HC Wainwright & Co. reiterated coverage of BELLUS Health with a rating of Buy and set a new price target of $16.00 from $14.00 previously
Evercore ISI Group reiterated coverage of BELLUS Health with a rating of Outperform and set a new price target of $20.00 from $12.00 previously
LONDON, June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE:GSK) and BELLUS Health Inc. (TSX:BLU) NASDAQ: BLU) today announced GSK has completed the acquisition of BELLUS, a biopharmaceutical company working to better the lives of patients suffering from refractory chronic cough (RCC), by way of a plan of arrangement in accordance with Section 192 of the Canada Business Corporations Act (the "Arrangement"). The Arrangement was approved by BELLUS' shareholders on 16 June 2023. As previously announced, the acquisition of BELLUS includes camlipixant, a potential best-in-class and highly selective P2X3 antagonist currently in phase III development for the first-line treatment of adult patients with R
Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events (≤6.5%); treatment emergent adverse event profile comparable to placebo Company also provides an update on its P2X3 pipeline and BLU-5937 Phase 2a trial for the treatment of chronic pruritus Company to host conference call and webcast at 8:00 a.m. ET BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC"